1-12 of 12
C. Patrick Reynolds
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Fenretinide via NOXA Induction, Enhanced Activity of the BCL-2 Inhibitor Venetoclax in High BCL-2–Expressing Neuroblastoma Preclinical Models

Thinh H. Nguyen, Balakrishna Koneru, Sung-Jen Wei, Wan Hsi Chen, Monish Ram Makena, Eduardo Urias, Min H. Kang, C. Patrick Reynolds
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12): 2270–2282.
https://doi.org/10.1158/1535-7163.MCT-19-0385
Published: 02 December 2019
View article titled, Fenretinide via NOXA Induction, Enhanced Activity of the BCL-2 Inhibitor Venetoclax in High BCL-2–Expressing Neuroblastoma Preclinical Models
Open the PDF for Fenretinide via NOXA Induction, Enhanced Activity of the BCL-2 Inhibitor Venetoclax in High BCL-2–Expressing Neuroblastoma Preclinical Models in another window
Includes: Supplementary data
Journal Articles

Abstract LB-B13: Pediatric Preclinical Testing Consortium evaluation of the CHK1 inhibitor prexasertib

Kristina A. Cole, Peter J. Houghton, Raushan T. Kurmasheva, Richard Gorlick, E. Anders Kolb, Min Kang, C. Patrick Reynolds, Xiao-Nan Li, Holly Lindsay, Stephen W. Erickson, Yuelong Guo, Beverly A. Teicher, Malcolm A. Smith, John M. Maris
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): LB-B13.
https://doi.org/10.1158/1535-7163.TARG-17-LB-B13
Published: 01 January 2018
View article titled, Abstract LB-B13: Pediatric Preclinical Testing Consortium evaluation of the CHK1 inhibitor prexasertib
Journal Articles

Reactive Oxygen Species–Mediated Synergism of Fenretinide and Romidepsin in Preclinical Models of T-cell Lymphoid Malignancies

Monish R. Makena, Balakrishna Koneru, Thinh H. Nguyen, Min H. Kang, C. Patrick Reynolds
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (4): 649–661.
https://doi.org/10.1158/1535-7163.MCT-16-0749
Published: 02 April 2017
View article titled, Reactive Oxygen Species–Mediated Synergism of Fenretinide and Romidepsin in Preclinical Models of T-cell Lymphoid Malignancies
Open the PDF for Reactive Oxygen Species–Mediated Synergism of Fenretinide and Romidepsin in Preclinical Models of T-cell Lymphoid Malignancies in another window
Includes: Supplementary data
Journal Articles

Reactive Oxygen Species Mediates the Synergistic Activity of Fenretinide Combined with the Microtubule Inhibitor ABT-751 against Multidrug-Resistant Recurrent Neuroblastoma Xenografts

Nancy E. Chen, N. Vanessa Maldonado, Vazgen Khankaldyyan, Hiroyuki Shimada, Michael M. Song, Barry J. Maurer, C. Patrick Reynolds
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (11): 2653–2664.
https://doi.org/10.1158/1535-7163.MCT-16-0156
Published: 01 November 2016
View article titled, Reactive Oxygen Species Mediates the Synergistic Activity of Fenretinide Combined with the Microtubule Inhibitor ABT-751 against Multidrug-Resistant Recurrent Neuroblastoma Xenografts
Open the PDF for Reactive Oxygen Species Mediates the Synergistic Activity of Fenretinide Combined with the Microtubule Inhibitor ABT-751 against Multidrug-Resistant Recurrent Neuroblastoma Xenografts in another window
Includes: Supplementary data
Journal Articles

Abstract C106: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the PI3K inhibitor XL147 (SAR245408).

C. Patrick Reynolds, Min H. Kang, Hernan Carol, Richard B. Lock, Richard Gorlick, E. Anders Kolb, Denise Alexander, Raushan T. Kurmasheva, Stephen T. Keir, John M. Maris, Jianrong Wu, Peter J. Houghton, Malcolm A. Smith
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): C106.
https://doi.org/10.1158/1535-7163.TARG-11-C106
Published: 12 November 2011
View article titled, Abstract C106: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the PI3K inhibitor XL147 (SAR245408).
Journal Articles

Abstract C105: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the CD56-targeting antibody-drug conjugate lorvotuzumab mertansine.

Peter J. Houghton, John M. Maris, Stephen T. Keir, Richard B. Lock, Hernan Carol, Richard Gorlick, E. Anders Kolb, Min H. Kang, C. Patrick Reynolds, Raushan T. Kurmasheva, Kathleen R. Whiteman, Malcolm Anders Smith
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): C105.
https://doi.org/10.1158/1535-7163.TARG-11-C105
Published: 12 November 2011
View article titled, Abstract C105: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the CD56-targeting antibody-drug conjugate lorvotuzumab mertansine.
Journal Articles

Antagonism of Cytotoxic Chemotherapy in Neuroblastoma Cell Lines by 13-cis-Retinoic Acid Is Mediated by the Antiapoptotic Bcl-2 Family Proteins

Michael D. Hadjidaniel, C. Patrick Reynolds
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (12): 3164–3174.
https://doi.org/10.1158/1535-7163.MCT-10-0078
Published: 14 December 2010
View article titled, Antagonism of Cytotoxic Chemotherapy in Neuroblastoma Cell Lines by 13-<em>cis</em>-Retinoic Acid Is Mediated by the Antiapoptotic <em>Bcl-2</em> Family Proteins
Open the PDF for Antagonism of Cytotoxic Chemotherapy in Neuroblastoma Cell Lines by 13-<em>cis</em>-Retinoic Acid Is Mediated by the Antiapoptotic <em>Bcl-2</em> Family Proteins in another window
Journal Articles

Inhibition of the Insulin-Like Growth Factor I Receptor by Epigallocatechin Gallate Blocks Proliferation and Induces the Death of Ewing Tumor Cells

Hyung-Gyoo Kang, Jasmine M. Jenabi, Xian Fang Liu, C. Patrick Reynolds, Timothy J. Triche, Poul H.B. Sorensen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (5): 1396–1407.
https://doi.org/10.1158/1535-7163.MCT-09-0604
Published: 09 May 2010
View article titled, Inhibition of the Insulin-Like Growth Factor I Receptor by Epigallocatechin Gallate Blocks Proliferation and Induces the Death of Ewing Tumor Cells
Open the PDF for Inhibition of the Insulin-Like Growth Factor I Receptor by Epigallocatechin Gallate Blocks Proliferation and Induces the Death of Ewing Tumor Cells in another window
Includes: Supplementary data
Journal Articles

Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program

Peter J. Houghton, Christopher L. Morton, Richard Gorlick, Richard B. Lock, Hernan Carol, C. Patrick Reynolds, Min H. Kang, John M. Maris, Stephen T. Keir, E. Anders Kolb, Jianrong Wu, Amy W. Wozniak, Catherine A. Billups, Larry Rubinstein, Malcolm A. Smith
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (1): 101–112.
https://doi.org/10.1158/1535-7163.MCT-09-0952
Published: 12 January 2010
View article titled, Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program
Open the PDF for Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program in another window
Includes: Supplementary data
Journal Articles

Abstract C57: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of AZD8055 an inhibitor of mTOR Kinase

Peter J. Houghton, John M. Maris, Josh Courtright, Henry S. Friedman, Stephen T. Keir, Richard B. Lock, Hernan Carol, E. Anders Kolb, Richard Gorlick, Min Kang, C. Patrick Reynolds, Christopher L. Morton, Malcolm A. Smith
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): C57.
https://doi.org/10.1158/1535-7163.TARG-09-C57
Published: 10 December 2009
View article titled, Abstract C57: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of AZD8055 an inhibitor of mTOR Kinase
Journal Articles

A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations

Tomas Frgala, Ondrej Kalous, Robert T. Proffitt, C. Patrick Reynolds
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (3): 886–897.
https://doi.org/10.1158/1535-7163.MCT-04-0331
Published: 15 March 2007
View article titled, A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations
Open the PDF for A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations in another window
Journal Articles

Transduction of green fluorescent protein increased oxidative stress and enhanced sensitivity to cytotoxic drugs in neuroblastoma cell lines

Hiroaki Goto, Bo Yang, Denise Petersen, Karen A. Pepper, Paul A. Alfaro, Donald B. Kohn, C. Patrick Reynolds
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2003) 2 (9): 911–917.
Published: 10 October 2003
View article titled, Transduction of green fluorescent protein increased oxidative stress and enhanced sensitivity to cytotoxic drugs in neuroblastoma cell lines
Open the PDF for Transduction of green fluorescent protein increased oxidative stress and enhanced sensitivity to cytotoxic drugs in neuroblastoma cell lines in another window